Uncovering Parkinson’s Earliest Footprints: The Tiny Brain Changes That Could Hold Big Clues

What if we could spot Parkinson’s Disease before the symptoms even begin—before the tremors, stiffness, or slowness ever appear? A new study published in Nature Communications may have brought us one step closer to doing just that. Scientists have zoomed in on a small region of the brain, the putamen, and uncovered surprising early damage at the microscopic level—long before the neurons themselves start to die off. The research team, made up of scientists from several institutions, studied brain tissue donated by people who had Parkinson’s, people with signs of early brain changes but no symptoms (known as incidental Lewy body disease), and people with healthy brains. Their goal was to track what happens first in the disease process—where it all begins—and what they found was both eye-opening and hopeful. At the heart of their investigation was a protein called alpha-synuclein, already known to play a central role in Parkinson’s. Normally, this protein helps nerve cells communicate. But in Parkinson’s, something goes wrong. It misfolds, clumps, and becomes toxic. The team focused on two particular forms of this rogue protein—one that’s phosphorylated (called pSer129), and one that’s truncated (called CTT122)—and looked at exactly where they were turning up in the brain. What they discovered is that damage doesn’t seem to start in the nerve cell bodies, as once thought. It starts at the synapses—the tiny contact points where nerve cells send signals to one another. And remarkably, the pSer129 version of alpha-synuclein shows up at these synapses early on, even before there’s visible damage to the main parts of the neurons. This suggests Parkinson’s may begin in the connections between cells—not in the cells themselves. In brains from people with early disease, these synapses were already showing signs of distress: swelling, breakdown, and chemical changes. The more pSer129 was present, the worse the damage. As the disease progressed, the CTT122 form of the protein also appeared, reinforcing the idea that alpha-synuclein is not only a marker of disease but may be actively driving it. This could change the way we think about Parkinson’s. Traditionally, the disease has been diagnosed based on visible symptoms and the presence of large clumps of alpha-synuclein called Lewy bodies. But this study suggests that damage begins much earlier, in smaller, more subtle ways. And that opens up a crucial window of opportunity—for detecting Parkinson’s before it fully takes hold, and for developing therapies that target the earliest changes. If scientists can develop a way to scan for this pSer129 protein at synapses, or to block its buildup, it might be possible to delay or even prevent the nerve damage that causes Parkinson’s symptoms in the first place. In other words, we may be catching Parkinson’s in the act—at the very moment when it starts to cause trouble. And that’s not just fascinating science—it’s the beginning of hope for earlier detection and more effective treatment.